전체메뉴
검색
Article Search

JMB Journal of Microbiolog and Biotechnology

QR Code QR Code

Articles Service

Supplementary
Share this article on :

Related articles in JMB

More Related Articles

Research article

References

  1. Chaires JB, Herrera JE, Waring MJ. 1990. Preferential binding of daunomycin to 5’TACG and 5’TAGC sequences revealed by footprinting titration experiments. Biochemistry 29: 6145-6153.
    Pubmed CrossRef
  2. Singal PK, Siveski-Iliskovic N, Hill M, Thomas TP, Li T. 1995. Combination therapy with probucol prevents adriamycininduced cardiomyopathy. J. Mol. Cell. Cardiol. 27: 1055-1063.
    CrossRef
  3. Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, et al. 2016. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14). Eur. J. Cancer 58: 112-121.
    Pubmed CrossRef
  4. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. 2009. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 86: 151-164.
    Pubmed PMC CrossRef
  5. Gold L. 1995. Oligonucleotides as research, diagnostic, and therapeutic agents. J. Biol. Chem. 270: 13581-13584.
    Pubmed CrossRef
  6. Bates PJ, Reyes-Reyes EM, Malik MT, Murphy EM, O’toole MG, Trent JO. 2017. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms. Biochim. Biophys. Acta Gen. Subj. 1861: 1414-1428.
    Pubmed CrossRef
  7. Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN, Harzstark AL, et al. 2014. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest. New Drugs 32: 178-187.
    Pubmed PMC CrossRef
  8. Park JY, Cho YL, Chae JR, Moon SH, Cho WG, Choi YJ, et al. 2018. Gemcitabine-incorporated G-Quadruplex aptamer for targeted drug delivery into pancreas cancer. Mol. Ther. Nucleic Acids 12: 543-553.
    Pubmed PMC CrossRef
  9. Reyes-Reyes EM, Teng Y, Bates PJ. 2010. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 70: 817-829.
    Pubmed PMC CrossRef
  10. Fonseca NA, Rodrigues AS, Rodrigues-Santos P, Alves V, Gregorio AC, Valerio-Fernandes A, et al. 2015. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination. Biomaterials 69: 76-88.
    Pubmed CrossRef
  11. Qiu W, Zhou F, Zhang Q, Sun X, Shi X, Liang Y, et al. 2013. Overexpression of nucleolin and different expression sites both related to the prognosis of gastric cancer. APMIS 121: 919-925.
    Pubmed CrossRef
  12. Berger CM, Gaume X, Bouvet P. 2015. The roles of nucleolin subcellular localization in cancer. Biochimie 113: 78-85.
    Pubmed CrossRef
  13. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, et al. 2003. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J. Clin. Oncol. 21: 3249-3254.
    Pubmed CrossRef
  14. Ueno H, Kiyosawa K, Kaniwa N. 2007. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br. J. Cancer 97: 145-151.
    Pubmed PMC CrossRef
  15. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. 1991. Action of 2’, 2’-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51: 6110-6117.
  16. Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, et al. 2009. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res. 15: 2913-2919.
    Pubmed CrossRef
  17. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, et al. 1998. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 58: 4349-4357.
  18. Vrignaud S, Benoit J-P, Saulnier P. 2011. Strategies for the nanoencapsulation of hydrophilic molecules in polymerbased nanoparticles. Biomaterials 32: 8593-8604.
    Pubmed CrossRef
  19. Amrutkar M, Gladhaug I. 2017. Pancreatic cancer chemoresistance to gemcitabine. 9(11). pii: E157. doi: 10.3390/cancers9110157.
    Pubmed PMC CrossRef
  20. Li L, Xiang D, Shigdar S, Yang W, Li Q, Lin J, et al. 2014. Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells. Int. J. Nanomedicine 9: 1083-1096.
    Pubmed PMC CrossRef
  21. Zhou W, Zhou Y, Wu J, Liu Z, Zhao H, Liu J, et al. 2014. Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells. J. Drug Target. 22: 57-66.
    Pubmed CrossRef
  22. Ray P, Cheek MA, Sharaf ML, Li N, Ellington AD, Sullenger BA, et al. 2012. Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. Nucleic Acid Ther. 22: 295-305.
    Pubmed PMC CrossRef
  23. Shahidi-Hamedani N, Shier WT, Moghadam Ariaee F, Abnous K, Ramezani M. 2013. Targeted gene delivery with noncovalent electrostatic conjugates of sgc-8c aptamer and polyethylenimine. J. Gene. Med. 15: 261-269
    Pubmed CrossRef
  24. Bagalkot V, Farokhzad OC, Langer R, Jon S. 2006. An aptamer–doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl. 45: 8149-8152.
    Pubmed CrossRef
  25. Vogus DR, Evans MA, Pusuluri A, Barajas A, Zhang M, Krishnan V, et al. 2017. A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer. J. Control. Release 267: 191-202.
    Pubmed CrossRef
  26. Vogus DR, Pusuluri A, Chen R, Mitragotri S. 2018. Schedule dependent synergy of gemcitabine and doxorubicin: Improvement of in vitro efficacy and lack of in vitro-in vivo correlation. Bioeng. Trans. Med. 3: 49-57.
    Pubmed PMC CrossRef
  27. Ling Y-H, El-Naggar AK, Priebe W, Perez-Soler R. 1996. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol. Pharmacol. 49: 832-841.
  28. Matthews DJ, Yakes M, Chen J, Tadano M, Bornheim L, Clary DO, et al. 2007. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6: 104-110.
    Pubmed CrossRef
  29. Xu X, Hamhouyia F, Thomas SD, Burke TJ, Girvan AC, McGregor WG, et al. 2 001. I nhibition o f DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J. Biol. Chem. 276: 43221-43230.
    Pubmed CrossRef
  30. Hovanessian AG, Soundaramourty C, El Khoury D, Nondier I, Svab J, Krust B. 2010. Surface expressed nucleolin is constantly induced in tumor cells to mediate calciumdependent ligand internalization. PLoS One 5: e15787.
    Pubmed PMC CrossRef